AstraZeneca Hong Kong President Sian Ng On The Pros And Cons Of The Hong Kong Market: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive SummaryHong Kong is increasingly viewed, and judged, in the shadow of Mainland China, which has seen explosive growth in recent years and has become the top emerging markets priority for most Big Pharma. This perception, however, obscures the reality that Hong Kong remains an independent and vibrant market, where new drugs are often approved more quickly than on the mainland.
You may also be interested in...
Major changes are afoot in Hong Kong’s drug approval and regulatory process with safety a prime focus following a series of reforms implemented last year in response to six deaths from spurious generic drugs in 2009.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).